Global Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Landscape Professional Research Report 2024

Global Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Landscape Professional Research Report 2024



Research Summary

Duchenne Muscular Dystrophy (DMD) drugs are medications specifically developed to address the symptoms and underlying causes of DMD, a genetic disorder characterized by progressive muscle degeneration and weakness. These drugs may include corticosteroids, which can help slow muscle deterioration and delay the loss of function. Emerging treatments encompass gene therapies designed to correct or replace the faulty dystrophin gene responsible for DMD, potentially offering more targeted and transformative approaches to managing the disease. DMD drugs aim to improve muscle function, mobility, and overall quality of life for individuals affected by this condition, representing significant advancements in the medical management of DMD.

According to DIResearch's in-depth investigation and research, the global Duchenne Muscular Dystrophy (DMD) Therapeutics market size will reach XX US$ Million in 2024, and is expected to reach XX US$ Million in 2030, with a CAGR of XX% (2025-2030). Among them, the China market has changed rapidly in the past few years. The market size in 2024 will be XX US$ Million, accounting for approximately XX% of the world. It is expected to reach XX US$ Million in 2030, and the global share will reach XX%.

The major global manufacturers of Duchenne Muscular Dystrophy (DMD) Therapeutics include Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals etc. The global players competition landscape in this report is divided into three tiers. The first tiers is the global leading enterprise, which occupies a major market share, is in a leading position in the industry, has strong competitiveness and influence, and has a large revenue scale; the second tiers has a certain share and popularity in the market, actively follows the industry leaders in product, service or technological innovation, and has a medium revenue scale; the third tiers has a smaller share in the market, has a lower brand awareness, mainly focuses on the local market, and has a relatively small revenue scale.

This report studies the market size, price trends and future development prospects of Duchenne Muscular Dystrophy (DMD) Therapeutics. Focus on analysing the market share, product portfolio, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Duchenne Muscular Dystrophy (DMD) Therapeutics market. The report data covers historical data from 2019 to 2023, base year in 2024 and forecast data from 2025 to 2030.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Duchenne Muscular Dystrophy (DMD) Therapeutics market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Duchenne Muscular Dystrophy (DMD) Therapeutics industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Duchenne Muscular Dystrophy (DMD) Therapeutics Include:

Sarepta Therapeutics

PTC Therapeutics

Pfizer

Bristol-Myers Squibb

Italfarmaco

Santhera Pharmaceuticals

Duchenne Muscular Dystrophy (DMD) Therapeutics Product Segment Include:

Exondys

Emflaza

Translarna

Duchenne Muscular Dystrophy (DMD) Therapeutics Product Application Include:

Hospitals

Clinics

Home Care

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry PESTEL Analysis

Chapter 3: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Porter’s Five Forces Analysis

Chapter 4: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Major Regional Market Size and Forecast Analysis

Chapter 5: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources


1 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Overview
1.1 Product Definition and Statistical Scope
1.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Product by Type
1.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type, 2023 VS 2024 VS 2030
1.2.2 Exondys
1.2.3 Emflaza
1.2.4 Translarna
1.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Product by Application
1.3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application, 2023 VS 2024 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Home Care
1.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue Analysis (2019-2030)
1.5 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Development Status and Trends
1.5.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Development Status Analysis
1.5.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Development Trends Analysis
2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market PESTEL Analysis
2.1 Political Factors Analysis
2.2 Economic Factors Analysis
2.3 Social Factors Analysis
2.4 Technological Factors Analysis
2.5 Environmental Factors Analysis
2.6 Legal Factors Analysis
3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Porter's Five Forces Analysis
3.1 Competitive Rivalry
3.2 Threat of New Entrants
3.3 Bargaining Power of Suppliers
3.4 Bargaining Power of Buyers
3.5 Threat of Substitutes
4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Analysis by Regions
4.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Overall Market: 2023 VS 2024 VS 2030
4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Forecast Analysis (2019-2030)
4.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue and Market Share by Region (2019-2024)
4.2.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Forecast by Region (2025-2030)
5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type and Application
5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
6 North America
6.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate Analysis (2019-2030)
6.2 North America Key Manufacturers Analysis
6.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
6.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
6.5 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
6.5.1 US
6.5.2 Canada
7 Europe
7.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate Analysis (2019-2030)
7.2 Europe Key Manufacturers Analysis
7.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
7.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
7.5 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
7.5.1 Germany
7.5.2 France
7.5.3 United Kingdom
7.5.4 Italy
7.5.5 Spain
7.5.6 Benelux
8 China
8.1 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate Analysis (2019-2030)
8.2 China Key Manufacturers Analysis
8.3 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
8.4 China Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
9 APAC (excl. China)
9.1 APAC (excl. China) Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate Analysis (2019-2030)
9.2 APAC (excl. China) Key Manufacturers Analysis
9.3 APAC (excl. China) Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
9.4 APAC (excl. China) Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
9.5 APAC (excl. China) Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
9.5.1 Japan
9.5.2 South Korea
9.5.3 India
9.5.4 Australia
9.5.5 Indonesia
9.5.6 Vietnam
9.5.7 Malaysia
9.5.8 Thailand
10 Latin America
10.1 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate Analysis (2019-2030)
10.2 Latin America Key Manufacturers Analysis
10.3 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
10.4 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
10.5 Latin America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
10.5.1 Mecixo
10.5.2 Brazil
11 Middle East & Africa
11.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size and Growth Rate Analysis (2019-2030)
11.2 Middle East & Africa Key Manufacturers Analysis
11.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Type
11.4 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Application
11.5 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country
11.5.1 Saudi Arabia
11.5.2 South Africa
12 Market Competition by Manufacturers
12.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Revenue by Key Manufacturers (2020-2024)
12.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Landscape Analysis and Market Dynamic
12.2.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Competitive Landscape Analysis
12.2.2 Global Key Manufacturers Headquarter and Key Area Sales
12.2.3 Market Dynamic
13 Key Companies Analysis
13.1 Sarepta Therapeutics
13.1.1 Sarepta Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.1.2 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
13.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.2 PTC Therapeutics
13.2.1 PTC Therapeutics Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.2.2 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
13.2.3 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.3 Pfizer
13.3.1 Pfizer Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.3.2 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
13.3.3 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.4 Bristol-Myers Squibb
13.4.1 Bristol-Myers Squibb Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.4.2 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
13.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.5 Italfarmaco
13.5.1 Italfarmaco Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.5.2 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
13.5.3 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
13.6 Santhera Pharmaceuticals
13.6.1 Santhera Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
13.6.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
13.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Market Data Analysis (Revenue, Gross Margin and Market Share) (2020-2024)
14 Industry Chain Analysis
14.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Chain Analysis
14.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Raw Material and Suppliers Analysis
14.2.1 Upstream Key Raw Material Supply Analysis
14.2.2 Raw Material Suppliers and Contact Information
14.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Typical Downstream Customers
14.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Sales Channel Analysis
15 Research Findings and Conclusion
16 Methodology and Data Source
16.1 Methodology/Research Approach
16.2 Research Scope
16.3 Benchmarks and Assumptions
16.4 Date Source
16.4.1 Primary Sources
16.4.2 Secondary Sources
16.5 Data Cross Validation
16.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings